SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Marksans Pharma trades jubilantly on acquiring US based Time-Cap Laboratories

30 Jun 2015 Evaluate

Marksans Pharma is currently trading at Rs. 63.25, up by 4.50 points or 7.66% from its previous closing of Rs. 58.75 on the BSE.

The scrip opened at Rs. 58.85 and has touched a high and low of Rs. 64.40 and Rs. 58.85 respectively. So far 1338573 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 75.00 on 15-Apr-2015 and a 52 week low of Rs. 26.05 on 11-Jul-2014.

Last one week high and low of the scrip stood at Rs. 64.40 and Rs. 56.75 respectively. The current market cap of the company is Rs. 2419.04 crore.

The promoters holding in the company stood at 48.25% while Institutions and Non-Institutions held 14.47% and 37.28% respectively.

Marksans Pharma through its wholly owned subsidiary, Marksans Pharma Inc., has acquired 100% of the outstanding shares of Time-Cap Laboratories, Inc., a New York corporation having its principal office at Farmingdale, New York. With this acquisition, Marksans is strategically increasing its presence in the US market, which is the largest pharmaceutical market in the world.

Time-Cap Laboratories is a leading manufacturer and marketer of solid dose generic pharmaceuticals, including private label over-the-counter (OTC) medications, generic prescription drugs (Rx), and nutritional supplements. It manufactures over 50 unique products from its facility in Farmingdale, New York, including tablets, caplets, capsules and pellets. Time-Cap’s average annual revenue over the last four years is in excess of $30 million per annum, and it achieved an average annual adjusted EBITDA of approximately $4 million. The company presently has no debt.

Marksans Pharma is engaged in production of prescription drugs, caters in areas like oncology, gastroenterology, antidiabetic, cardiovascular, pain management, gynaecology and others.

 

Marksans Pharma Share Price

179.55 -0.95 (-0.53%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×